Skip to content
DataLookout
Menu

NCT07897734

TNG462-C103: Study to Evaluate the Safety, Tolerability, and Antitumor Activity of Vopimetostat in Combination With ERAS-0015 in PDAC and NSCLC Patients

StatusNot Yet Recruiting
PhasePhase 1/2
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 1 version: 1 with changes below.

  1. Study First Submitted

Endpoints

Primary

Phase 1 Maximum Tolerated Dose
Timeframe: 21 days
Phase 2 Combination Anti-neoplastic Activity
Timeframe: 12 weeks

Secondary (3)

Phase 1 and 2 Combination Anti-neoplastic Activity
Phase 1 and 2 PK Profile of vopimetostat and ERAS-0015 in Combination
Phase 1 and 2 Adverse Event Profile

Arms and interventions

Dose Escalation PDACExperimental

Escalating doses of vopimetostat in combination with ERAS-0015

Dose expansion 1L PDACExperimental

Expansion arm at the RD(s) of vopimetostat in combination with ERAS-0015

Dose Expansion 2L PDACExperimental

Expansion arm at the RD(s) of vopimetostat in combination with ERAS-0015

Dose Expansion 2L or 3L NSCLCExperimental

Expansion arm at the RD(s) of vopimetostat in combination with ERAS-0015

Drugs: vopimetostat, ERAS-0015